CClinicalTrials.gg
CompletedNCT00211172Updated Oct 9, 2014Results posted

HMO Research Network CERT: Acute Myocardial Infarction

An interventional study of Beta-blocker adherence after an AMI in Acute Myocardial Infarction (AMI), sponsored by Kaiser Permanente. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
836
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary goal of this study is to evaluate the effectiveness of direct-to-patient mailings designed to increase patient's adherence to prescribed beta-blockers following an acute myocardial infarction (AMI).

Prior to developing patient materials, focus groups were conducted with patient who had previously suffered an acute myocardial infarction (AMI) to identify the issues and information that patients felt were important to include in our materials as well as the best way to present the information. Additionally, patient materials were "pre-tested" with AMI patients to ensure that the materials were clear and easy to read and that the key messages were understood.

Read the detailed description

Specific Aims:

  1. Assess the persistence of beta blocker use for post-acute myocardial infarction (AMI) patients following a direct to patient intervention designed to increase rates of evidence-based long-term use of medications (beta blockers, lipid lowering agents, aspirin and ACE inhibitors) that increase survival following AMI.
  2. Describe patient and system characteristics associated with differences in impact of the intervention

Research Design and Methods:

We will conduct a randomized controlled trial within the 4 participating HMOs (Kaiser Permanente Northwest, Harvard Pilgrim Health Care, Health Partners, and Kaiser Permanente Georgia). Inpatient data will be used to identify patients with a primary discharge diagnosis of AMI 4-6 months before the extraction date. Practices will be block-randomized to the intervention group or to usual care. To increase repetition of the message, there will be two personalized mailings, occurring at 4-6 months post AMI, and at 9 months. The first message will include elements in the table below, and the repeat message will be shorter, but include similar information. The message will come from the patient's own health plan with the choice of specific individual (e.g. quality assurance department, medical director, or Chief of Cardiology) being informed by our qualitative work. This intervention will be done in collaboration with the cardiovascular care committees and quality assurance departments of participating Health Maintenance Organizations (HMOs).

02

Conditions studied

  • Acute Myocardial Infarction (AMI)

Keywords

  • Acute Myocardial Infarction (AMI)
  • Heart Attack
  • Adherence
  • Beta-blocker
  • Behavior change
03

In context

Myocardial Infarction

2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.

This study's enrollment of 836 is above the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of Acute Myocardial Infarction (AMI) from 12/1/03 to 5/31/04
  • Beta-blocker dispensing following AMI
  • Beta-blocker dispensing prior to intervention date

Exclusion criteria

Exclusion Criteria:

None

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
836 participants (actual)

Study arms

  • Experimental
    Beta-blocker adherence after an AMI

    Patients received two mailings about the importance of beta blocker use.

    Behavioral: Beta-blocker adherence after an AMI

  • No intervention
    Usual care

    Patients received usual care.

Interventions

  • BehavioralBeta-blocker adherence after an AMI

    The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.

    Also known as: Reminder mailing

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date

    The primary outcome measure adherence to B-blocker therapy post intervention. Adherence was measured by the degree of prescription filling in an interval derived from pharmacy prescription records by constructing a proportion-of-days-covered per-month measure, using the quantity dispensed and days supplied from each prescription

    Time frame: 9 months

07

Results

Posted Oct 9, 2014

Participant flow

Participant flow — Overall Study
MilestoneUsual CareReminder Mailing
Started449458
Completed410426
Not completed3932
Withdrew: Died or lost health plan eligibility3932

Outcome measures

PrimaryAdjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date

The primary outcome measure adherence to B-blocker therapy post intervention. Adherence was measured by the degree of prescription filling in an interval derived from pharmacy prescription records by constructing a proportion-of-days-covered per-month measure, using the quantity dispensed and days supplied from each prescription

Time frame:
9 months
Reported as:
Mean · Adjusted monthly % of days covered
Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date
Adjusted monthly % of days coveredUsual CareReminder Mailing
Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date66.37 ± 34.2570.62 ± 32.03

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care———
Reminder Mailing———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Usual CareReminder MailingTotal
Between 18 and 65 years53.72 ± 6.9853.50 ± 7.6853.61 ± 14.66
>=65 years76.58 ± 7.2177.64 ± 7.4177.11 ± 14.62
Age, Continuous
Age, Continuous(years)Usual CareReminder MailingTotal
Mean65.13 ± 13.4664.78 ± 14.2264.95 ± 27.68
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareReminder MailingTotal
Female153143296
Male296315611
Region of Enrollment
Region of Enrollment(participants)Usual CareReminder MailingTotal
United States449458907
08

Study locations

4 sites
  • Kaiser Permanente-Georgia
    Atlanta, Georgia 30305, United States
  • Harvard Pilgrim Healthcare
    Boston, Massachusetts 02115, United States
  • Health Partners
    Minneapolis, Minnesota 55440-1309, United States
  • Kaiser Permanent Center for Health Research
    Portland, Oregon 97227, United States
09

References and documents

Publications

  • Smith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Lane K, Goodman M, Nelson WW, Yang X, Soumerai SB. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008 Mar 10;168(5):477-83; discussion 483; quiz 447. doi: 10.1001/archinternmed.2007.132. PubMed 18332291 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00211172
Lead sponsor
Kaiser Permanente
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Sponsor
First posted
Sep 21, 2005
Start date
Oct 2003
Primary completion
Dec 2005
Completion
May 2009
Results posted
Oct 9, 2014
Last update
Oct 9, 2014

Study contacts

David H Smith, PhD
principal investigator · Kaiser Permanent Center for Health Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion